DEPOMED AND MADAUS S.R.L. ENTER INTO AGREEMENT FOR PROQUIN XR IN EUROPE

Depomed, Inc. (Nasdaq: DEPO) and Madaus S.r.l. today announced that the companies have entered into a distribution and supply agreement for ProQuin(R) XR, Depomed's once-daily, extended release formulation of the antibiotic ciprofloxacin. Under the terms of the agreement, Depomed has granted an exclusive right to Madaus for the commercialization of ProQuin XR in Europe and has agreed to supply Madaus with commercial quantities of ProQuin XR tablets in bulk form.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051129005487&newsLang=en)